Literature DB >> 2035629

Differential effect of hyperglycemia and hyperinsulinemia on pathways of hepatic glycogen repletion.

G I Shulman1, R A DeFronzo, L Rossetti.   

Abstract

To delineate the roles of hyperglycemia and insulin on the direct vs. indirect pathways of liver glycogen synthesis, we performed euglycemic (group I; n = 8), hyperglycemic (group II; n = 9), and euglycemic pharmacological hyperinsulinemic clamp studies (120 min) with an infusion of [1-13C]glucose in chronically catheterized conscious rats after a 24-h fast. Portal vein plasma glucose concentrations and portal vein plasma insulin concentrations, respectively, obtained at the end of the study in groups I-III were as follows: group I 110 +/- 4 mg/dl, 29 +/- 7 ng/ml; group II 219 +/- 7 mg/dl, 24 +/- 7 ng/ml; and group III 112 +/- 9 mg/dl, 174 +/- 25 ng/ml. Mean liver glycogen concentrations at the end of the three studies were 0.68 +/- 0.07, 1.22 +/- 0.08 (P less than 0.001 compared with groups I and III), and 0.60 +/- 0.17 g/100 g wet wt liver in groups I-III respectively, which yielded hepatic glycogen synthetic rates of 0.16 +/- 0.03, 0.41 +/- 0.04 (P less than 0.001 compared with groups I and III), and 0.13 +/- 0.08 mumol glucosyl U.g liver-1.min-1 in groups I-III, respectively. From the enrichments of 13C in the C-1 and C-6 positions of the glucosyl unit in glycogen compared with the enrichment in the C-1 position in portal vein glucose as determined by 13C- and 1H-NMR, the amount of glycogen synthesized by the direct pathway was calculated to be 18 +/- 2, 41 +/- 3 (P less than 0.0001 compared with groups I and III), and 17 +/- 3% in groups I-III, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2035629     DOI: 10.1152/ajpendo.1991.260.5.E731

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

1.  Mild Physiologic Hyperglycemia Induces Hepatic Insulin Resistance in Healthy Normal Glucose-Tolerant Participants.

Authors:  Devjit Tripathy; Aurora Merovci; Rita Basu; Muhammad Abdul-Ghani; Ralph A DeFronzo
Journal:  J Clin Endocrinol Metab       Date:  2019-07-01       Impact factor: 5.958

2.  Enhancement of the gluconeogenic flux of hepatic glycogen repletion by a phenacyl imidazolium compound in vivo.

Authors:  G W Cline; K Greenawalt; G I Shulman
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

3.  13C-nuclear magnetic resonance spectroscopy studies of hepatic glucose metabolism in normal subjects and subjects with insulin-dependent diabetes mellitus.

Authors:  G W Cline; D L Rothman; I Magnusson; L D Katz; G I Shulman
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

4.  Impaired net hepatic glycogen synthesis in insulin-dependent diabetic subjects during mixed meal ingestion. A 13C nuclear magnetic resonance spectroscopy study.

Authors:  J H Hwang; G Perseghin; D L Rothman; G W Cline; I Magnusson; K F Petersen; G I Shulman
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

5.  Thyroid hormone treatment decreases hepatic glucose production and renal reabsorption of glucose in alloxan-induced diabetic Wistar rats.

Authors:  Silvania da Silva Teixeira; Ana C Panveloski-Costa; Aline Carvalho; Fabiana P Monteiro Schiavon; Any de Castro Ruiz Marque; Raquel S Campello; Roberto B Bazotte; Maria T Nunes
Journal:  Physiol Rep       Date:  2016-09

6.  Metabolic control analysis of hepatic glycogen synthesis in vivo.

Authors:  Yuichi Nozaki; Max C Petersen; Dongyan Zhang; Daniel F Vatner; Rachel J Perry; Abudukadier Abulizi; Sofie Haedersdal; Xian-Man Zhang; Gina M Butrico; Varman T Samuel; Graeme F Mason; Gary W Cline; Kitt F Petersen; Douglas L Rothman; Gerald I Shulman
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-18       Impact factor: 11.205

7.  Exercise-Induced Improvements in Postprandial Glucose Response Are Blunted by Pre-Exercise Hyperglycemia: A Randomized Crossover Trial in Healthy Individuals.

Authors:  Steven Carter; Thomas P J Solomon
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-15       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.